7.48
+0.14(+1.91%)
Currency In USD
| Previous Close | 7.34 |
| Open | 7.39 |
| Day High | 7.77 |
| Day Low | 7.35 |
| 52-Week High | 21.57 |
| 52-Week Low | 5.41 |
| Volume | 2.81M |
| Average Volume | 1.42M |
| Market Cap | 649.24M |
| PE | -3.32 |
| EPS | -2.25 |
| Moving Average 50 Days | 6.23 |
| Moving Average 200 Days | 8.15 |
| Change | 0.14 |
If you invested $1000 in Kura Oncology, Inc. (KURA) since IPO date, it would be worth $498.33 as of August 18, 2025 at a share price of $7.475. Whereas If you bought $1000 worth of Kura Oncology, Inc. (KURA) shares 5 years ago, it would be worth $340.7 as of August 18, 2025 at a share price of $7.475.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kura Oncology to Report Second Quarter 2025 Financial Results
GlobeNewswire Inc.
Jul 31, 2025 11:30 AM GMT
SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report second
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress
GlobeNewswire Inc.
Jun 12, 2025 11:30 AM GMT
– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML – – 93% (41/44) and 89% (24/27) CRc observed in NPM1-m
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
GlobeNewswire Inc.
Jun 02, 2025 10:00 PM GMT
– CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients – – Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified subgroups, regardless of prior HSCT, prior venetoclax, o